The U.S. Court of Appeals for the Federal Circuit (CAFC) ruled in a precedential decision authored by Judge Prost on Monday that certain claims of Janssen Pharmaceuticals Inc.’s patent for a schizophrenia drug are not indefinite but vacated and remanded the district court’s finding that Teva Pharmaceuticals had not proven all of the claims obvious.
Recent Posts
- Federal Circuit Highlights Differences in Statutory and Article III Standing in Patent Cases
- Witnesses Tell Senate IP Subcommittee They Must Get NO FAKES Act Right
- Commerce Department Announces NIST and USPTO Actions on AI
- FCC Restores Net Neutrality Regime Amid Criticism
- Other Barks and Bites for Friday, April 26: World Intellectual Property Day Celebrated Around the Globe; China Tops List for AI Patents Granted; EPO Releases Cleantech Study on World IP Day